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Letters to the Editor598s glycoprotein IIb/IIIa is typically used after and not before the
hronic total occlusion has been crossed with a guidewire with
easonable assurance that the wire is intraluminal distally. There-
ore, we question whether glycoprotein IIb/IIIa use has any impact
n chronic total occlusion success rates. Further, its inclusion in
he models can potentially impact the point estimates of other
mportant variables. More importantly, the use of glycoprotein
Ib/IIIa before successful crossing of a chronic total occlusion may
ncrease the risk of pericardial effusion or tamponade. It would be
f interest to conduct the same analysis without the inclusion of
lycoprotein IIb/IIIa to observe whether other important variables
re predictive of success and outcome in this cohort.
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eply
rs. Shishehbor and Whitlow raise an excellent point regarding
ur analysis of predictors of procedural success in chronic total
cclusion (CTO) angioplasty (1). There are several aspects regard-
ng the use of glycoprotein (GP) IIb/IIIa antagonist use in CTO
ercutaneous coronary intervention (PCI) that need to be recog-
ized to put the results of our analysis in context. First, GP
Ib/IIIa antagonists were used in the later years of our analysis.
econd, GP IIb/IIIa antagonists were administered after successful
rossing of the target lesion in CTO PCI in the vast majority of
ases. Third, GP IIb/IIIa is not a patient pre-procedural variable
nd thus is subject to important selection bias. We think including
P IIb/IIIa antagonist use in our model is justified to evaluate the
ossibility of both benefit and harm. In our analysis there did not
eem to be any signal for harm. However, their use in the manner
escribed above does bias this analysis. We have described tech-
ical success (crossing the lesion and performing angioplasty with
r without stenting and 40% residual stenosis) as well as
rocedural success (technical success without major adverse clinical
vents while in the hospital). Therefore, using GP IIb/IIIa
ntagonists only in patients who have already had a successful
rossing of their CTO lesion does increase the likelihood that they
ill have procedural success by the virtue of being well on the wayo technical success. We agree wholeheartedly that these agents
hould be administered only after the lesion has been crossed and
ntraluminal wire position has been confirmed.
We have repeated the analysis excluding GP IIb/IIIa antagonist
se from the model, and the point estimates for the other variables
re not significantly altered. In conclusion, we thank Drs. Shishe-
bor and Whitlow for raising this important point regarding the
se of GP IIb/IIIa antagonists in CTO angioplasty and allowing
s to expand on this important element of CTO PCI.
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merican Board of Internal
edicine Maintenance of
ertiﬁcation Requirements
he recent article by Drs. Dangas and Popma (1) provided
aluable information about the importance of Maintenance of
ertification (MOC).
I am writing to clarify some details regarding the American
oard of Internal Medicine (ABIM) interventional cardiology
OC requirements:
ABIM encourages interventional cardiologists to enroll in
MOC as early as possible during their 10-year certification
cycle. This allows flexibility as to when and how they complete
the MOC requirements.
Physicians do not have to earn 100 self-assessment points prior
to sitting for the exam. They can earn some or all points before
or after the exam.
In addition to completing ABIM-offered Practice Improvement
Modules (PIMs), there are additional avenues for cardiologists
to earn credit toward self-evaluation of practice performance.
Data collected for 2 ACC initiatives, the National Cardiovas-
cular Data Registry (NCDR) and the Door to Balloon (D2B)
Alliance are both recognized by ABIM for MOC credit.
